Fact CheckerSign in

NCT02692872Active, not recruiting

Screening for Alpha Thalassemia in Healthy Volunteers

Screening for Alpha Globin Deletions

Source: ClinicalTrials.gov · Last updated 24 Apr 2026

Brief summary (registry, in English)

Background: Alpha thalassemia is a blood disorder. It is caused by genetic deletions. Part of the DNA is missing from a group of genes called alpha globin. Alpha thalassemias are some of the most common genetic deletions. We are testing for alpha thalassemia trait. Alpha thalassemia trait is when someone has only two out of the normal four alpha globin genes. In some people, they lead to no symptoms. Others have changes that lead to disease, including mild anemia. Researchers want to learn more about alpha thalassemia and blood vessels. This may allow them to develop new treatments for blood diseases such as sickle cell disease. Objective: To better understand how alpha globin deletions in healthy people affect blood vessels. Eligibility: Healthy volunteers ages 18-39 who self-report African ancestry. Design: Participants will provide a one-time saliva sample. This can be by mail, in-person at a study event, or at NIH. Participants will get a small kit to collect their saliva sample. The kit has easy instructions. The sample does not need to be put in the refrigerator. Participants will spit a small amount of saliva (less than half a teaspoon) into a collection tube. Participants will close the funnel lid tightly, and then unscrew the funnel lid from the tube. They will then close the tube tightly with the small cap provided and shake the tube for 5 seconds. Participants will place the tube in the provided envelope and mail it to NIH. The specimen will be stored and processed in the lab. Participants may be invited to participate in more research studies, whether or not researchers find that they have alpha thalassemia trait.

Status (registry)
Active, not recruiting
Study type
Observational
Enrollment
367 (actual)
First submitted
25 Feb 2016
Start date
17 Apr 2017
Primary completion date
31 Dec 2027
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Diseases
Thalassaemia
NCT number
NCT02692872

What you commit to

  • Study type: Observational
  • Participants enrolled: 367
  • From 17 Apr 2017 to the primary completion date, 31 Dec 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • There are no exclusion criteria for this screening protocol

Criteria the registry did not label

  • INCLUSION CRITERIA:
    • Subject report of the following:
  • Age 18 - 39
  • Self-report of African ancestry
  • Willingness and legal ability to give and sign informed study consent

Age in the registry: 18 years to 39 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
National Institutes of Health Clinical Center
Coordinator of this site? Confirm its status
BethesdaUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.